VEGFA and cancer: Fischer et al. [14] suggest that once patients with advanced cancer are administered anti-angiogenic therapy, the expression of other pro-angiogenic factors (e.g., SDF-1, FGF-1, FGF-2, etc.)is significantly increased, eventually leading to the failure of anti-VEGF treatment.